Physician Views: Are EU5 prescribers eager for biosimilar Humira?

AbbVie's TNF inhibitor Humira is the world's biggest selling drug by some margin (2017 sales of $18.4 billion), but faces EU patent expiry later this year. This event could play a pivotal role in shaping the biosimilars market; payers are understandably eager to get their hands on biosimilar versions, but what about prescribers? - We are snap-polling rheumatologists, gastroenterologists and dermatologists in the EU5 markets to find out…

Earlier this month, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for marketing authorisation of a proposed biosimilar adalimumab (Hyrimoz) from Novartis. Assuming full approval from the European Commission, Hyrimoz will be indicated for the treatment of certain inflammatory and autoimmune disorders, including rheumatoid arthritis, psoriasis, Crohn's disease and ulcerative colitis, and could launch in certain European markets in October 2018. Amongst your physician group, how would you rate the level of pent-up demand for a cost-effective adalimumab biosimilar in your country?





Very significant

If Humira (the originator medicine) and an adalimumab biosimilar were both available to you for prescribing, which of these statements best describes your treatment practice?

I would prescribe an adalimumab biosimilar to a patient upon treatment initiation

I would switch patients from Humira to an adalimumab biosimilar when a patient is clinically stable

I would switch patients to an adalimumab biosimilar when a patient has had a poor clinical response to Humira

I will prescribe whatever I’m told to by local payers

I would only use Humira, and would not prescribe adalimumab biosimilars to my patients under any circumstances

In your opinion, what do you believe will be the key driver of uptake of adalimumab biosimilars in your country? (Select three)

Lower costs

Clinical data (e.g. efficacy, safety, etc.)

Physician familiarity/experience/comfort with biosimilars

Key opinion leader (KOL) endorsement

Fewer reimbursement restrictions on prescribing biosimilars, compared with branded agents

Promotional efforts by biosimilar companies

Educational programmes

Patient advocacy endorsement

Health authorities/payers dictating biosimilar prescribing


In your opinion, how influential will payers be in terms of driving uptake of adalimumab biosimilars in your country?

Not at all influential

Slightly influential

Moderately influential

Very influential

Extremely influential

One year after the launch of adalimumab biosimilars in your country, what proportion of total prescriptions do you expect adalimumab biosimilars to ​account for across all of Humira's key indications, including rheumatoid arthritis, inflammatory bowel disease and psoriasis?

0-10 percent

10-25 percent

25-50 percent

50-75 percent

Above 75 percent

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions. Note: FirstWord Polls are powered by Medefield MedePolls, a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties and over 100 markets. To conduct this poll with a different audience, or an entirely different poll, contact us at

To read more Physician Views articles, click here.